source
- Dr McGregor on Key End Points of the STRIKE Trial of Tivozanib Plus Pembrolizumab in RCCBradley McGregor, MD, discusses the end points that will be evaluated in the phase 3 STRIKE trial of adjuvant tivozanib plus pembrolizumab in high-risk RCC.onclive · 2mo ago↗ source
- Dr Kuykendall on the Evolving JAK Inhibitor and Transplant Considerations in MyelofibrosisAndrew Kuykendall, MD, explains considerations for JAK inhibitor sequencing and the use of transplant in myelofibrosis.onclive · 2mo ago↗ source
- Vertex earnings get muted investor responseWhile overall revenue fell just shy of Wall Street forecasts, sales of the gene editing medicine Casgevy and pain drug Journavx missed analyst estimates by double-digit percentages.